Potential anticancer therapiesviaCXCL5 and its receptors

CXCL5 Promotes Prostate Cancer Progression

(2015) Lesa A Begley et al.   NEOPLASIA

Cxcr2 and Cxcl5 regulate the IL-17/G-CSF axis and neutrophil homeostasis in mice

(2012) Junjie Mei et al.   JOURNAL OF CLINICAL INVESTIGATION

SB-656933, a novel CXCR2 selective antagonist, inhibits ex vivo neutrophil activation and ozone-induced airway inflammation in humans

(2011) Aili L. Lazaar et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Interleukin-6 as a Therapeutic Target in Human Ovarian Cancer

(2011) Jermaine Coward et al.   CLINICAL CANCER RESEARCH

Inhibition of neutrophil infiltration into A549 lung tumors in vitro and in vivo using a CXCR2-specific antagonist is associated with reduced tumor growth

(2011) Simon Tazzyman et al.   INTERNATIONAL JOURNAL OF CANCER

CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis

(2011) Bin-Zhi Qian et al.   NATURE

Retraction Note to: Retraction: CXCR2 mediates NADPH oxidase–independent neutrophil extracellular trap formation in cystic fibrosis airway inflammation

(2011) Veronica Marcos et al.   NATURE MEDICINE

Small-Molecule Antagonists for CXCR2 and CXCR1 Inhibit Human Melanoma Growth by Decreasing Tumor Cell Proliferation, Survival, and Angiogenesis

(2009) S. Singh et al.   CLINICAL CANCER RESEARCH

CC chemokine ligand 2 (CCL2) promotes prostate cancer tumorigenesis and metastasis

(2009) Jian Zhang et al.   CYTOKINE & GROWTH FACTOR REVIEWS

CXCR2 antagonists for the treatment of pulmonary disease

(2008) R.W. Chapman et al.   PHARMACOLOGY & THERAPEUTICS